Skip to main content
  1. Home
  2. Emerging Tech
  3. Photography
  4. News

NASA stitched together thousands of Hubble images to create this mesmerizing galaxy zoom

Add as a preferred source on Google

Do you ever think about how small we are in comparison to the rest of the galaxy? How about the universe? This week, NASA released a time lapse video simulating a visual trip to the center of the galaxy. Using wide-field images of the Milky Way taken by the Hubble Space Telescope, NASA simulates a journey of 27,000 light years — from the tiny speck that is planet Earth, all the way into the very center of the galaxy we call home.

One of the must shocking facts about this journey is that there are more than half a million stars at the core of the Milky Way galaxy. This nuclear star cluster is the most dense and massive group of stars in the entire galaxy. It’s hard to grasp just how dense the cluster is, but think of it in more local terms: to match the stellar density of the Milky Way’s nuclear star cluster, you’d have to stuff one million suns into the volume of space in the 4.3 light years between planet Earth and our closest neighbor star, Alpha Centauri.

Recommended Videos

A million suns! Once the time-lapse visualization does reach the center of the Milky Way, we get a brief glimpse of the many stars surrounding the supermassive black hole known as Sagittarius A*. Of course, we can’t capture photos of Sagittarius A* since it is impossible to observe a black hole directly, but astronomers and scientists are often able to identify black holes in space by studying the orbital patterns and trajectories of stars and planets in a particular region of space.

NASA’s video gives us just a glimpse of what would be a very, very long (and arduous, and to this day still physically impossible) trip to the center of our galaxy. Of course, this virtual version only takes 30 seconds and it isn’t quite the same as real life space travel, but for many of us, this beautiful taste of deep space exploration may be as close as we’re ever going to get.

Chloe Olewitz
Former Digital Trends Contributor
Chloe is a writer from New York with a passion for technology, travel, and playing devil's advocate. You can find out more…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more